Faron Pharmaceuticals Feed

2026-01-08 18:45:00 Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Advanced Amortisation of the First Tranche Bonds

2025-12-22 08:00:00 Faron announces strategic collaboration with The Institute for Cancer Research to launch BLAZE trial, targeting immunotherapy resistance in cancer 1,91 EUR | +1,59% | 0,90 MEUR

2025-12-17 15:30:00 Composition of Faron Pharmaceutical’s Shareholders’ Nomination Board 1,83 EUR | -0,87% | 0,38 MEUR

2025-12-11 09:30:00 Faron issues second tranche of bonds with an aggregated principal amount of EUR 10 million under its convertible bond arrangement 2,00 EUR | +3,52% | 0,87 MEUR

2025-12-08 08:00:00 Faron presents updated BEXMAB data at ASH 2025: Deep and durable responses in HR-MDS with favorable safety profile 2,00 EUR | -2,91% | 0,80 MEUR

2025-12-04 17:00:00 Faron Pharmaceuticals Ltd: Holding(s) in Company 2,06 EUR | +1,98% | 1,28 MEUR

2025-12-03 11:00:00 Faron Pharmaceuticals Ltd: Registration of New Shares 2,09 EUR | -1,42% | 0,44 MEUR

2025-12-03 08:00:00 Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First Tranche Bonds 2,09 EUR | -1,42% | 0,44 MEUR

2025-12-02 08:00:00 Faron Pharmaceuticals Ltd: Grant of Options 2,12 EUR | +0,71% | 0,17 MEUR

2025-12-01 08:00:00 Faron Pharmaceuticals Ltd: Appointment of CFO 2,10 EUR | -1,64% | 0,28 MEUR

2025-11-27 08:00:00 Faron’s Financial Calendar for 2026 2,19 EUR | +0,92% | 0,25 MEUR

2025-11-24 18:15:00 INSIDE INFORMATION: FARON INTENDS TO ISSUE SECOND TRANCHE OF BONDS WITH AN AGGREGATED PRINCIPAL AMOUNT OF EUR 10 MILLION UNDER ITS CONVERTIBLE BOND ARRANGEMENT 2,08 EUR | -6,92% | 1,55 MEUR

2025-11-04 08:00:00 Faron announces two bexmarilimab abstracts accepted at ASH 2025, including an oral presentation on treatment efficacy 2,30 EUR | -1,71% | 0,46 MEUR

2025-11-03 08:00:00 Faron hits key milestone with BEXMAB Phase 2 completion, advances to registrational trial with FDA alignment 2,34 EUR | +1,96% | 1,13 MEUR

2025-10-28 08:00:00 Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Advanced Amortisation of the First Tranche Bonds 2,16 EUR | -4,85% | 0,87 MEUR

2025-10-21 15:10:00 FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY 2,10 EUR | +0,24% | 0,93 MEUR

2025-10-20 08:00:00 Updated BEXMAB Phase I/II Data presented at ESMO 2025 shows further improvement, strengthening the clinical profile of bexmarilimab in treatment-naïve HR-MDS patients 2,10 EUR | -2,33% | 2,39 MEUR

2025-10-03 12:00:00 Faron Pharmaceuticals Ltd: Registration of New Shares 2,12 EUR | -1,16% | 0,42 MEUR

2025-10-03 08:00:00 Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First Tranche Bonds 2,12 EUR | -1,16% | 0,42 MEUR

2025-09-19 08:00:00 Faron Pharmaceuticals Ltd: Exercise of Options, Director Dealing and Issue of Equity 2,19 EUR | 0,00% | 0,36 MEUR

2025-09-12 17:25:00 Correction: FARON PHARMACEUTICALS LTD: HALF-YEAR FINANCIAL RESULTS 1 JANUARY – 30 JUNE 2025

2025-08-27 08:00:00 FARON PHARMACEUTICALS LTD: HALF-YEAR FINANCIAL RESULTS 1 JANUARY – 30 JUNE 2025 2,44 EUR | -6,33% | 2,27 MEUR

2025-08-19 08:00:00 Faron Pharmaceuticals Ltd: Notice of Half-Year Financial Results 2,65 EUR | +6,41% | 1,35 MEUR

2025-08-18 08:00:00 Inside Information: Faron to advance bexmarilimab into a registrational Phase 2/3 study in treatment-naïve (frontline) HR-MDS after positive meeting with the FDA 2,50 EUR | +5,05% | 2,16 MEUR

2025-08-08 16:00:00 Faron Pharmaceuticals Ltd: Holding(s) in Company 2,44 EUR | +1,24% | 0,82 MEUR

2025-08-08 09:30:00 Faron announces extension to its key patent family around bexmarilimab and targeting Clever-1 in cancers with a new US patent granted 2,44 EUR | +1,24% | 0,82 MEUR

2025-08-07 08:00:00 Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Advanced Amortisation of the First Tranche Bonds 2,41 EUR | -6,77% | 1,92 MEUR

2025-08-06 08:00:00 Inside Information: Faron to present updated BEXMAB data in frontline HR-MDS to FDA; complete remission rate substantially increased to 43% 2,58 EUR | +14,38% | 3,98 MEUR

2025-07-30 08:30:00 FARON ANNOUNCES ACCEPTANCE OF BEXMARILIMAB DATA FOR ORAL PRESENTATION AT ESMO 2025 2,19 EUR | -2,66% | 0,90 MEUR

2025-07-09 08:00:00 Faron announces acceptance of two studies involving bexmarilimab, one of them as an oral presentation, at the 19th International Congress of Immunology (IUIS) 2025 2,50 EUR | +0,60% | 0,56 MEUR

2025-07-02 12:00:00 Faron Pharmaceuticals Ltd: Director Dealing 2,58 EUR | +6,40% | 0,67 MEUR

2025-06-30 13:00:00 Faron Pharmaceuticals Ltd: Director/PCA Dealing 2,44 EUR | +7,00% | 1,05 MEUR

2025-06-30 08:00:00 Faron-supported research in Theranostics identifies secreted Clever-1 (sClever-1) as an independent driver of immune evasion in cancer, deepening the understanding of bexmarilimab’s mode of action 2,44 EUR | +7,00% | 1,05 MEUR

2025-06-12 08:00:00 Faron Pharmaceuticals presents updated Phase II data from BEXMAB Study at EHA 2025 2,73 EUR | +0,18% | 0,37 MEUR

2025-06-05 17:00:00 Faron Pharmaceuticals Ltd: Director/PCA Dealing and Donation of Shares to Foundation 2,55 EUR | +1,19% | 0,97 MEUR

2025-06-03 13:00:00 Faron Pharmaceuticals Ltd: Registration of New Shares 2,70 EUR | -10,60% | 2,97 MEUR

2025-06-03 08:00:00 Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First Tranche Bonds 2,70 EUR | -10,60% | 2,97 MEUR

2025-06-02 08:00:00 Faron Pharmaceuticals presents Phase II data from BEXMAB Study at ASCO 2025 3,02 EUR | -3,05% | 2,62 MEUR

2025-05-30 08:00:00 Faron announces publication of full Phase I BEXMAB study data in Lancet Haematology 3,12 EUR | +6,86% | 3,57 MEUR

2025-05-27 18:00:00 Faron Pharmaceuticals Ltd: Issue of Treasury Shares to the Company 2,92 EUR | -4,43% | 1,45 MEUR

2025-05-27 08:00:00 Faron’s Bexmarilimab demonstrates immune-activating and drug-sensitizing potential in myeloid malignancies 3,05 EUR | +5,90% | 1,28 MEUR

2025-05-23 08:00:00 Faron announces new data that highlight patient populations with cancer that are most likely to benefit from first-in-class immunotherapy bexmarilimab 2,88 EUR | -3,52% | 1,99 MEUR

2025-05-21 08:00:00 Faron Appoints Ralph Hughes as Chief Business Officer (CBO) 2,87 EUR | +4,36% | 1,39 MEUR

2025-05-15 08:00:00 Faron Announces Acceptance of Bexmarilimab Data for Oral Presentation at EHA 2025 Congress 2,59 EUR | -1,89% | 0,60 MEUR

2025-05-14 15:00:00 Faron Pharmaceuticals Ltd: Grant of Options 2,64 EUR | -1,49% | 0,40 MEUR

2025-05-12 08:00:00 Faron Pharmaceuticals presents promising Phase 1/2 data from BEXMAB Study at MDS 2025 plenary session 2,65 EUR | -4,68% | 1,16 MEUR

2025-04-24 08:00:00 Faron announces acceptance of bexmarilimab Phase II data for oral presentation at ASCO 2025 2,42 EUR | -1,02% | 0,39 MEUR

2025-04-17 14:15:00 Holding in Company 2,44 EUR | +6,09% | 3,51 MEUR

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Faron Pharmaceuticals

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden